AMAG News Alert Amag Pharmaceuticals (AMAG) 41.49 02/14/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 10:25 AM

Amag Pharmaceuticals (AMAG) 41.49 $AMAG

A Look at the Latest Happenings in Health Care Sector: New Research on Alliqua, Almost Family, Alnylam Pharmaceuticals, Alphatec Holdings, and AMAG Pharmaceuticals
PR Newswire - Thu Feb 12, 7:30AM CST
Editor Note: For more information about this release, please scroll to bottom.
ATEC: 1.34 (unch), AFAM: 30.88 (+0.37), ALNY: 95.54 (+1.67), AMAG: 41.49 (+0.23), ALQA: 6.14 (+0.09)

World Intravenous (IV) Iron Drugs Industry
PR Newswire - Tue Feb 10, 11:39AM CST
This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 17 companies including many key and niche players such as -
ACT: 285.37 (+3.71), AMAG: 41.49 (+0.23)

AMAG's Q4 Loss Narrows Y/Y, Reiterates 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 9:30AM CST
AMAG Pharmaceuticals (AMAG) reported a fourth-quarter 2014 loss of 2 cents per share, narrower than the year-ago loss of 17 cents per share.
OPHT: 51.11 (+0.12), AMAG: 41.49 (+0.23), PRTA: 22.89 (+0.13)

AMAG Pharmaceuticals' (AMAG) CEO Bill Heiden on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Feb 09, 9:45PM CST

AMAG: 41.49 (+0.23)

AMAG Pharmaceuticals (AMAG) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Feb 09, 3:25PM CST

AMAG: 41.49 (+0.23)

AMAG Pharmaceuticals EPS of $4.67
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:16PM CST

AMAG: 41.49 (+0.23)

AMAG Announces Final Fourth Quarter and Year End 2014 Financial Results
GlobeNewswire - Mon Feb 09, 3:12PM CST
Conference call scheduled for 4:30 p.m. ET today
AMAG: 41.49 (+0.23)

Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Feb 08, 4:35PM CST

CCK: 50.65 (+0.74), MXL: 8.37 (+0.09), TDW: 30.01 (+1.45), MOH: 59.66 (+0.26), DAC: 5.86 (-0.01), PRI: 55.09 (+0.55), ICUI: 88.98 (+0.42), NEWP: 20.29 (-0.01), CSC: 66.10 (+1.60), GSM: 15.60 (+0.06), QLYS: 47.95 (+1.46), AMAG: 41.49 (+0.23), AMKR: 8.90 (-0.02), NTES: 112.99 (-0.49), IPHI: 19.17 (-1.48), GIG: 1.19 (+0.05), ALSN: 31.88 (+0.24), KS: 32.52 (-0.35), SSNI: 9.15 (+0.36), CMP: 91.66 (+0.52), COUP: 11.06 (-0.07), MRH: 36.05 (-0.54), NBIX: 37.22 (+0.27), MODN: 11.64 (-0.01), RLD: 12.65 (+0.16), DNB: 133.27 (+0.46), WCN: 46.05 (-0.42), MCC: 9.44 (+0.15), CRK: 6.09 (+0.46), OTTR: 31.27 (unch), MERU: 2.74 (-0.01)

Sanofi Misses on Q4 Earnings, Maintains Diabetes Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:04AM CST
Sanofi (SNY) reported fourth-quarter 2014 business earnings of 87 cents per ADS, 2 cents below the Zacks Consensus Estimate.
BIIB: 391.66 (-0.45), AMAG: 41.49 (+0.23), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)

Teva Beats on Q4 Earnings By a Penny, Maintains Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Feb 06, 8:01AM CST
Teva (TEVA) expects to earn $5.00 - $5.30 per share on revenues of $19 - $19.4 billion in 2015.
IPXL: 39.51 (+0.69), BIIB: 391.66 (-0.45), TEVA: 56.77 (-0.58), AMAG: 41.49 (+0.23)

bluebird bio's Thalassemia Drug Gets Breakthrough Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 5:20PM CST
bluebird bio, Inc.'s (BLUE) LentiGlobin BB305 received Breakthrough status from the FDA for transfusion-dependent patients with beta-thalassemia major.
BLUE: 90.70 (+0.93), BIIB: 391.66 (-0.45), AMGN: 153.48 (+0.30), AMAG: 41.49 (+0.23)

AMAG Pharmaceuticals, Inc. to Participate in the Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 4:00PM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's president and chief executive officer, will participate in an analyst-led fireside chat at the Leerink Global Healthcare Conference in New York, NY. The fireside chat will take place on Wednesday, February 11, 2015 at 8:00 a.m. ET during which management will discuss the company's financial results, business update, regulatory status, and growth prospects.
AMAG: 41.49 (+0.23)

Perrigo Beats on Earnings, FY15 Guidance In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 9:15AM CST
Perrigo reported second quarter fiscal 2015 earnings of $1.82 per share.
BIIB: 391.66 (-0.45), PRGO: 150.90 (+0.22), ALNY: 95.54 (+1.67), AMAG: 41.49 (+0.23)

Shares of AMAG Up 99.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Feb 05, 9:06AM CST
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on August 11th, 2014 at $20.91. In approximately 6 months, AMAG Pharmaceuticals has returned 99.76% as of today's recent price of $41.76.
AMAG: 41.49 (+0.23)

Allergan Beats Earnings Yet Again on Strong Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 8:52AM CST
Allergan (AGN) reported fourth-quarter 2014 earnings of $2.17 per share, above the Zacks Consensus Estimate of $1.82.
AGN: 229.49 (+1.87), BIIB: 391.66 (-0.45), ACT: 285.37 (+3.71), AMAG: 41.49 (+0.23)

Glaxo Posts In Line Q4 Earnings, HIV Segment Sales Grow - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 8:05AM CST
GlaxoSmithKline (GSK) reported fourth-quarter core earnings of 86 cents per ADS, down 1% year over year at CER.
AGN: 229.49 (+1.87), AMAG: 41.49 (+0.23), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)

Amgen Reveals Positive Results on Biosimilar Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 3:25PM CST
Amgen Inc. (AMGN) announced encouraging results from a phase III study on ABP 501.
AMGN: 153.48 (+0.30), ABBV: 58.05 (+1.00), AMAG: 41.49 (+0.23)

AMAG Pharmaceuticals, Inc. to Host Conference Call on February 9, 2015 at 4:30 p.m. ET to Discuss Financial Results for the Quarter and Year Ended 2014
GlobeNewswire - Tue Feb 03, 5:30PM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will report unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014 on Monday, February 9, 2015 after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with slides at 4:30 p.m. ET during which management will discuss the company's financial results, business update, regulatory status, and growth prospects.
AMAG: 41.49 (+0.23)

Repros Files for Androxal in the U.S. for Hypogonadism - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 5:15PM CST
Repros Therapeutics Inc. (RPRX) submitted a NDA for its lead candidate, Androxal.
RPRX: 8.76 (+0.09), ABBV: 58.05 (+1.00), AMAG: 41.49 (+0.23), CELG: 115.88 (+0.16)

Biogen Idec (BIIB) Shows Strength: Stock Moves Up 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 7:51AM CST
Biogen Idec Inc. (BIIB) was a big mover last session, as the company saw its shares rise over 10% on the day.
BIIB: 391.66 (-0.45), AMAG: 41.49 (+0.23)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WIN Expands Leadership Amidst Rapid Growth Surge

Why WIN's Leadership Shake-Up Matters Change is afoot at the fertility and family support powerhouse WIN, and there's no mistaking the bold handwriting on the wall. As they swell towards supporting one million families, WIN's revamping their leadership table with three key players aimed at pushing the envelope further than before. They've got Claudio Stefan, Stacey...

JiMMYBAR! Unveils World's First Creatine Trail Mix

The New Face of Snacking: Creatine Trail Mix I'll tell you right off the bat, JiMMYBAR! seems to be cornering the snack world with an odd—but interesting—twist. They've just launched the world's first Creatine + Protein Trail Mix, blending muscle-building nutrients with the classic crunch of trail mix. Sounds quirky, and it’s exclusive to their site, JiMMYBARs.com....

Vayo Debuts as Booking Holdings Eyes $100M Investment

A travel revolution might just be on the horizon, courtesy of Booking Holdings' latest venture, Vayo. And they’re talking about throwing $100 million into it—subject to a few conditions, sure—but that’s not pocket change you toss around without a serious plan. Transforming Travel into a Seamless Experience Vayo’s got one job: making your travels less like a...

Marshall Goldman Expands Footprint with Marino Acquisition

Revving Up in Florida: Marshall Goldman's Strategic Leap If you're tuned into the luxury car scene, you probably already heard Marshall Goldman is making moves into Florida. Buying Marino Performance Motors of West Palm Beach isn't just another notch on their belt—it's a strategic leap into their second-largest market. This ain't merely about showroom floor space. Think...

Jaguar Promise Tackles College Cost for Texas Students

Transforming Aspirations into Achievements In the heart of San Antonio, something’s cooking at A&M University-San Antonio, and it's not just the classic breakfast tacos. They've hit a record-breaking enrollment of 7,697 students this Fall, with 1,322 being fresh-faced first-timers. And while that might grab your attention, the real headliner is their Jaguar Promise...

Puori Protein Transparency Pays Off Amid Lead Scare

Puori's Moment of Reckoning The world of nutritional supplements is no stranger to controversy, but when Puori found itself caught in the storm of the Consumer Reports investigation last year, it chose a road less traveled: transparency and accountability. Faced with alarming news that over two-thirds of tested protein powders exceeded California's Proposition 65 lead...

Wagner Logistics Gears Up for Major Expansion in Liberty

Imagine waking up to news like this: Wagner Logistics is laying down some serious roots in Liberty, MO. They’ve snagged a deal with a local manufacturer that’s got them renting out over 830,000 square feet of warehouse space. Seems Wagner's got a knack for living large. More Than Just a Warehouse Gig Wagner's not just popping up another dusty shelf space; they're...

xFusion Tackles Cooling and Power at OCP 2026

Bracing for an AI Revolution Ah, the world of AI — it's like the wild west out there, with data centers struggling to keep up as workloads skyrocket. Enter xFusion, a veteran in the computing infrastructure game, rolling out some seriously impressive tech at the 2026 Open Compute Project (OCP) Global Summit. The company's latest offering showcases how they're tackling...

FCS Drives Key FDA Approvals in Cancer Treatment

Florida Cancer Specialists: Changing the Cancer Treatment Game Some organizations toot their horns, but every now and then, a group truly shakes up the playing field. Take Florida Cancer Specialists & Research Institute (FCS), for instance. Over years of relentless research, FCS has nailed its role in securing two significant FDA approvals aimed at expanding treatment...

Tessa AI: Revolutionizing Biomedical Research with AI

Shaking Up Research Evaluation When Siensmetrica decided it was high time for a name change, morphing into Tessa AI wasn't just a cosmetic shift. It was a nod to what stakeholders were already calling it and laid the ground for a broader mission statement. They're not sitting on their hands; they're crafting tools that tackle the scientific life cycle from start to...